Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies worldwide.
Solid track record with excellent balance sheet.
Share Price & News
How has Omnicell's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OMCL's share price has been volatile over the past 3 months.
7 Day Return
US Healthcare Services
1 Year Return
US Healthcare Services
Return vs Industry: OMCL underperformed the US Healthcare Services industry which returned 14% over the past year.
Return vs Market: OMCL underperformed the US Market which returned -15.9% over the past year.
Price Volatility Vs. Market
How volatile is Omnicell's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StDoes Omnicell, Inc. (NASDAQ:OMCL) Have A Volatile Share Price?
2 months ago | Simply Wall StInvestors Who Bought Omnicell (NASDAQ:OMCL) Shares Five Years Ago Are Now Up 165%
2 months ago | Simply Wall StDo You Know About Omnicell, Inc.’s (NASDAQ:OMCL) ROCE?
Is Omnicell undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OMCL ($65.23) is trading below our estimate of fair value ($79.12)
Significantly Below Fair Value: OMCL is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: OMCL is poor value based on its PE Ratio (44.1x) compared to the Healthcare Services industry average (41.1x).
PE vs Market: OMCL is poor value based on its PE Ratio (44.1x) compared to the US market (12.2x).
Price to Earnings Growth Ratio
PEG Ratio: OMCL is poor value based on its PEG Ratio (1.7x)
Price to Book Ratio
PB vs Industry: OMCL is good value based on its PB Ratio (3.3x) compared to the US Healthcare Services industry average (3.3x).
How is Omnicell forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OMCL's forecast earnings growth (25.2% per year) is above the savings rate (1.7%).
Earnings vs Market: OMCL's earnings (25.2% per year) are forecast to grow faster than the US market (13.4% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: OMCL's revenue (10.4% per year) is forecast to grow faster than the US market (7% per year).
High Growth Revenue: OMCL's revenue (10.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: OMCL's Return on Equity is forecast to be low in 3 years time (8.4%).
How has Omnicell performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OMCL has high quality earnings.
Growing Profit Margin: OMCL's current net profit margins (6.8%) are higher than last year (4.8%).
Past Earnings Growth Analysis
Earnings Trend: OMCL's earnings have grown by 19.9% per year over the past 5 years.
Accelerating Growth: OMCL's earnings growth over the past year (62.6%) exceeds its 5-year average (19.9% per year).
Earnings vs Industry: OMCL earnings growth over the past year (62.6%) exceeded the Healthcare Services industry 23.3%.
Return on Equity
High ROE: OMCL's Return on Equity (7.3%) is considered low.
How is Omnicell's financial position?
Financial Position Analysis
Short Term Liabilities: OMCL's short term assets ($483.2M) exceed its short term liabilities ($237.0M).
Long Term Liabilities: OMCL's short term assets ($483.2M) exceed its long term liabilities ($158.6M).
Debt to Equity History and Analysis
Debt Level: OMCL's debt to equity ratio (5.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if OMCL's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: OMCL's debt is well covered by operating cash flow (290%).
Interest Coverage: OMCL's interest payments on its debt are well covered by EBIT (17.7x coverage).
What is Omnicell's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OMCL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate OMCL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OMCL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OMCL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OMCL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Randy Lipps (62yo)
Mr. Randall A. Lipps, also known as Randy, founded Omnicell, Inc. in September 1992 and has been its Chief Executive Officer and President since October 2002. Mr. Lipps had been Executive Chairman and Exec ...
CEO Compensation Analysis
Compensation vs Market: Randy's total compensation ($USD6.34M) is about average for companies of similar size in the US market ($USD5.71M).
Compensation vs Earnings: Randy's compensation has increased by more than 20% in the past year.
|Executive VP & CFO||4.67yrs||US$2.47m||0.14% $3.9m|
|Executive VP of Marketing||8.08yrs||US$2.02m||0.072% $2.1m|
|Executive VP & Chief Commercial Officer||2yrs||US$2.40m||0.084% $2.4m|
|Senior VP||2.5yrs||no data||0.033% $952.7k|
|Senior VP & Chief Information Officer||0.58yr||no data||no data|
|Executive VP||5.17yrs||US$1.16m||0.071% $2.0m|
|Senior VP & Chief Marketing officer||0.58yr||no data||no data|
|Senior VP & Chief Human Resources Officer||0.58yr||no data||no data|
|Executive Vice President of Engineering & Integration Management Officer||12.75yrs||no data||0.082% $2.4m|
Experienced Management: OMCL's management team is considered experienced (3.6 years average tenure).
|Lead Independent Director||no data||US$286.21k||0.045% $1.3m|
|Independent Director||7.25yrs||US$224.95k||0.072% $2.1m|
|Independent Director||17yrs||US$251.97k||0.088% $2.5m|
|Independent Director||6.25yrs||US$231.22k||0.037% $1.1m|
|Independent Director||7.92yrs||US$229.97k||0.088% $2.5m|
|Independent Director||0.92yr||no data||0.0048% $137.3k|
|Independent Director||5.92yrs||US$224.95k||0.048% $1.4m|
Experienced Board: OMCL's board of directors are considered experienced (6.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: OMCL insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.7%.
Omnicell, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Omnicell, Inc.
- Ticker: OMCL
- Exchange: NasdaqGS
- Founded: 1992
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: US$2.855b
- Shares outstanding: 42.47m
- Website: https://www.omnicell.com
Number of Employees
- Omnicell, Inc.
- 590 East Middlefield Road
- Mountain View
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|OMCL||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Aug 2001|
|OC9||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Aug 2001|
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies worldwide. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility’s in-house information management systems; and robotic dispensing systems used in hospitals and retail pharmacies for handling the stocking and retrieval of boxed medications. In addition, the company provides single dose automation solutions to fill and label for incoming prescriptions; medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings; automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; and semi-automated filling equipment for the long-term care institutional pharmacy. Further, it offers Omnicell Patient Engagement, a web-based nexus of solutions; and patient communication tools, such as interactive voice response, outbound communications, and mobile app. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/07 05:46|
|End of Day Share Price||2020/04/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.